News
Stories by Tim Boreham
Health & Biotech
Dr Boreham’s Crucible: Picture this – a growth stock that makes money, pays divvies and accrues cash
Health & Biotech
Bargain Barrel: Buys in the battered ASX biotech sector? Ask Boreham!
Health & Biotech
Dr Boreham’s Crucible: A Pfizer takeover could make Resapp a genuine chestbeater
Health & Biotech
Dr Boreham’s Crucible: Putting Microba under the microscope
Health & Biotech
Dr Boreham’s Crucible: Can RATs in the ranks lead Atomo to our home-testing utopia?
Health & Biotech
Dr Boreham’s Crucible: Mayne focuses on razzle-dazzle as oral contraceptive approaches the stage
Tech
HealthKick Podcast: Audeara’s revenue up nearly 140pc YoY… and 50pc from the previous quarter
Health & Biotech
Dr Boreham’s Crucible: A cure for the common cold? Why Firebrick Pharma might pass the sniff test
Health & Biotech
Dr Boreham’s Crucible: Does EBR have the ticker to tackle the charge cable conundrum?
Health & Biotech
Dr Boreham’s Crucible: Can fans of the ‘green whistle’ breathe easier as (if) Covid fades away?
Health & Biotech